Cannara Biotech Inc.
LOVE.V
TSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.58% | 28.40% | 25.18% | 30.37% | 41.53% |
| Total Other Revenue | 108.49% | 195.90% | 335.18% | 34.31% | -15.42% |
| Total Revenue | 27.84% | 28.80% | 25.43% | 30.64% | 41.86% |
| Cost of Revenue | 12.69% | 14.54% | 25.13% | 54.14% | 71.39% |
| Gross Profit | 54.37% | 52.50% | 25.84% | 2.99% | 9.01% |
| SG&A Expenses | 14.91% | 17.24% | 20.39% | 43.09% | 43.96% |
| Depreciation & Amortization | 11.60% | 25.03% | 24.52% | 15.01% | 41.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.49% | 14.50% | 23.06% | 49.31% | 61.18% |
| Operating Income | 178.30% | 143.71% | 38.36% | -40.38% | -34.74% |
| Income Before Tax | 299.69% | 214.98% | 111.84% | -41.96% | -37.47% |
| Income Tax Expenses | 351.28% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.52% | 182.88% | 109.88% | -28.60% | -9.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.52% | 182.88% | 109.88% | -28.60% | -9.91% |
| EBIT | 178.30% | 143.71% | 38.36% | -40.38% | -34.74% |
| EBITDA | 99.94% | 86.50% | 29.13% | -25.40% | -17.01% |
| EPS Basic | 98.46% | 188.97% | 115.23% | -27.19% | -7.66% |
| Normalized Basic EPS | 772.73% | 468.71% | 86.20% | -67.49% | -70.97% |
| EPS Diluted | 118.24% | 223.33% | 136.64% | -28.12% | -15.43% |
| Normalized Diluted EPS | 793.68% | 463.70% | 84.41% | -68.47% | -72.06% |
| Average Basic Shares Outstanding | 0.88% | -0.24% | -0.81% | -0.50% | 0.25% |
| Average Diluted Shares Outstanding | 1.58% | 0.76% | 0.49% | 0.34% | 1.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |